Givinostat in Duchenne Muscular Dystrophy: Natural history comparison applying propensity score matching
David Gómez‐Andrés(Vall d'Hebron Hospital Universitari), P. Bettica(Italfarmaco (Italy)), Mercedes López Lobato, Simone Cazzaniga(Centro Studi GISED), Valeria Sansone(University of Milan), Krista Vandenborne(University of Florida), Mariacristina Scoto(University College London), Yann Péréon(European Organisation for Rare Diseases), Craig M. McDonald(University of California Davis Medical Center), N. Coceani(Italfarmaco (Italy)), Claudio Bruno(Istituto Giannina Gaslini), Riccardo Masson, H. Phan(Rare Disease Therapeutics (United States)), Michela Guglieri(Muscular Dystrophy UK)
Cited by 0
Related Papers
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management
|The Lancet Neurology|2009|2k
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
|The Lancet Neurology|2009|1.2k
Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study
|Neuromuscular Disorders|2019|636
<i><scp>LTBP4</scp></i> genotype predicts age of ambulatory loss in duchenne muscular dystrophy
|Annals of Neurology|2012|242
Autologous Transplantation of Muscle-Derived CD133+ Stem Cells in Duchenne Muscle Patients
|Cell Transplantation|2007|230